BCFC / iStockphoto.com
A CRISPR patent owned by the Broad Institute of Harvard and MIT is “unpatentable for indefiniteness”, according to an agriculture biotech company.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Benson Hill Biosystems, The Broad Institute of Harvard and MIT, Editas Medicine, CRISPR technology, gene-editing, post-grant review, patent invalidation